Serrated Pathway Colorectal Cancer in the Population: an alternative to the adenoma-carcinoma sequence

Joanne P Young ^1*, Mark A Jenkins ², Susan Parry ³, Bruce W Young ⁴, Derek J Nancarrow ¹, Dallas R English ², Graham G Giles ⁵ and Jeremy R Jass ⁶

¹ QIMR, Australia
² University of Melbourne, Australia
³ Middlemore Hospital, New Zealand
⁴ QUT, Australia
⁵ Cancer Council Victoria, Australia
⁶ St Marks Hospital, United Kingdom

^* To whom correspondence should be addressed. E-mail: joanne.young{at}qimr.edu.au.

Accepted 12 May 2007

Abstract

A significant proportion of colorectal cancer (CRC) develops through the serrated neoplasia pathway. Such tumours show a distinctive molecular phenotype of somatic BRAF mutations and widespread concordant methylation events in CpG islands (CIMP). These features are also observed in the polyps developing in individuals with hyperplastic polyposis syndrome (HPS). In HPS, multiple serrated polyps develop in the colorectum, and approximately 50% of cases present with at least one CRC. Observations of rare affected sibships including identical twins, suggest a recessive or co-dominant mode of inheritance. In addition, up to 50% of individuals with HPS report a family history of CRC. At a population level, recent work has demonstrated that patients with serrated pathway cancers characterized by BRAF mutation are four times more likely to have a family history of CRC than patients with common CRC. These findings suggest an increased genetic predisposition for serrated pathway CRC in the wider population. We propose that HPS results from the inheritance of two putative co-dominant alleles in approximately 1 in 2000 individuals. Therefore carriers of one co-dominant allele may number up to 1 in 25, and it is likely that these carriers are at increased risk of CRC, accounting for, at least in part, the burden of serrated pathway CRC in the population. This proposition may have important implications for screening and prevention of CRC in individuals who have an increased risk for development of serrated pathway cancers, namely those with multiple, proximal, large or advanced serrated polyps, and their relatives.

Keywords: BRAF mutation, familial colorectal cancer, genetic predisposition, hyperplastic polyposis syndrome, serrated neoplasia

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Ogino, S., Nosho, K., Kirkner, G. J, Kawasaki, T., Meyerhardt, J. A, Loda, M., Giovannucci, E. L, Fuchs, C. S (2009). CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58: 90-96 [Abstract] [Full Text]  
• English, D. R., Young, J. P., Simpson, J. A., Jenkins, M. A., Southey, M. C., Walsh, M. D., Buchanan, D. D., Barker, M. A., Haydon, A. M., Royce, S. G., Roberts, A., Parry, S., Hopper, J. L., Jass, J. J., Giles, G. G. (2008). Ethnicity and Risk for Colorectal Cancers Showing Somatic BRAF V600E Mutation or CpG Island Methylator Phenotype. Cancer Epidemiol. Biomarkers Prev. 17: 1774-1780 [Abstract] [Full Text]  
• Hassan, C., Pickhardt, P., Laghi, A., Kim, D., Zullo, A., Iafrate, F., Di Giulio, L., Morini, S. (2008). Computed Tomographic Colonography to Screen for Colorectal Cancer, Extracolonic Cancer, and Aortic Aneurysm: Model Simulation With Cost-effectiveness Analysis. Arch Intern Med 168: 696-705 [Abstract] [Full Text]